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Purpose. To investigate the topical iontophoresis of valaciclovir (VCV) as a means to improve cutaneous
aciclovir (ACV) delivery.
Methods. ACV and VCV electrotransport experiments were conducted using excised porcine skin in
vitro.
Results. While the charged nature of the prodrug, VCV, enabled it to be more efficiently iontophoresed
into the skin than the parent molecule, ACV, only the latter was detectable in the receptor chamber,
suggesting that VCV was enzymatically cleaved into the active metabolite during skin transit.
Iontophoresis of VCV was significantly more efficient than that of ACV; the cumulative permeation
of ACV after 1, 2 and 3 h of VCV iontophoresis at 0.5 mA cmj2 and using an aqueous 2 mM (õ0.06%)
formulation was 20 T 10, 104 T 47 and 194 T 82 mg cmj2, respectively (cf. non-quantifiable levels, 0.1 and
1.0 T 0.7 mg cmj2 after ACV iontophoresis).
Conclusions. These delivery rates provide ample room to reduce either current density or the duration
of current application. Preliminary in vitro data serve to emphasize the potential of VCV iontophoresis
to improve the topical therapy of cutaneous herpes simplex infections and merit further investigation to
demonstrate clinical efficacy.
KEY WORDS: aciclovir; herpes simplex virus; iontophoresis; prodrug; transdermal delivery; valaciclovir
hydrochloride.
INTRODUCTION
The successful topical treatment of cutaneous herpes
simplex virus (HSV) infections using aciclovir (ACV; Fig. 1a)
offers several advantages over systemic therapy: the drug can
be directly targeted to its site of action, reducing circulating
drug levels and hence, attendant adverse effects. However,
topical ACV creams, though extensively evaluated, have
demonstrated only modest efficacy that is also partly
dependent on a number of pathophysiological parameters,
e.g., the type and phase of infection (primary vs. recurrent;
early vs. latent), the severity of infection and the patient’s
immune status (1,2). Moreover, most studies investigating
ointment formulations have shown little or no clinical benefit
in the treatment of cutaneous lesions e.g., herpes labialis
(3Y7). This vehicle effect has been attributed to the slightly
improved permeation of ACV from creams relative to
ointments as demonstrated across human (8) and guinea pig
(9,10) skin in vitro. Although the inability of ACV to
efficiently penetrate the stratum corneum (SC) barrier has
been proposed as one of the principal reasons for inadequate
topical ACV therapy (1,8), a dermatopharmacokinetic study
has shown that while total epidermal concentrations of ACV
subsequent to topical delivery are superior to those attained
after oral administration, the latter appears to deliver more
drug to the basal epidermis, the site of infection (11).
Formulation strategies to enhance cutaneous ACV perme-
ation have included the incorporation of enhancers such as
dimethyl sulfoxide (8,9) and the use of polymeric vehicles
(12).
Iontophoresis, the application of a small electrical
current to facilitate the transport of charged molecules into
and across the skin (13,14), has also been investigated as a
means to increase cutaneous ACV bioavailability (15Y19).
This technique enables the non-invasive, controlled adminis-
tration of therapeutic agents for either local or systemic
action, and has recently culminated in the commercialization
of a device incorporating lidocaine for local anaesthesia in
infants prior to superficial dermatological procedures
(LidoSitei, Vyteris, Inc., Fair Lawn, NJ) (13,20). The
LidoSitei device, in which the positively charged lidocaine
participates in the electrical circuit by transporting charge
from the anodal compartment into the skin, results in local
anaesthesia within 10 minVwithin which period the drug
reaches the nerves located in the dermis and epidermis.
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Although the delivery of therapeutic amounts of ACV
into human skin in vitro after 30 min of current application
followed by 5 h of passive delivery has been reported (albeit
with a formulation pH of 3) (17), ACV is not an ideal
candidate for topical iontophoresis as it is essentially
uncharged at physiological pH (pKa1 2.27; pKa2 9.25) and
has a low aqueous solubility (1.3 mg/ml at pH 7.4, 25-C (11)).
In comparison, valaciclovir (VCV; Fig. 1a), the L-valyl ester
prodrug of ACV (21,22) possesses three ionizable groups
with pKa values of 1.90, 7.47 and 9.43. Consequently, VCV is
õ50% protonated at physiological pH, and more suited to
iontophoresis relative to its active metabolite, ACV (Fig. 1c).
VCV is rapidly and extensively converted to ACV by
intestinal and/or first pass hepatic metabolism subsequent to
oral administration (23,24). Although, to-date, VCV has not
been used topically, the considerable esterase activity within
the skin (25Y27), together with the physical chemistry of
VCV, suggest that this prodrug may prove to be an ideal
candidate for cutaneous iontophoresis.
The iontophoresis of ester prodrugs, in particular
lipophilic alkyl ester prodrugs, has been the subject of several
studies (28Y31). However, the use of an amino acid ester
prodrug to augment the charged nature of a drug, and thus its
iontophoretic permeation, has not been studied in detail. The
concept has been exploited for delivering dehydroepiandros-
terone (DHEA); iontophoresis of the ionized glycyl ester of
DHEA led to a modest three-fold increase in permeation
through rabbit skin, compared to the parent DHEA (32).
The aim of this study was to investigate the iontopho-
retic delivery of VCV, exploiting its positive charge to
facilitate electrotransport across the skin and to rely on
cutaneous esterase activity to release increased amounts of
ACV at or near the site of infectionVthe basal epidermis.
The prodrug approach would thus be expected to ameliorate
treatment of cutaneous herpetic infections by targeting
therapeutic levels of drug to this tissue layer without the
undue systemic exposure associated with oral and parenteral
delivery.
MATERIALS AND METHODS
Materials
ACV and MeCN (Acetonitrile Chromasolv\ for HPLC,
gradient grade) were purchased from Sigma-Aldrich (Saint
Quentin Fallavier, France). Acetaminophen, sodium chloride
(NaCl), di-sodium hydrogen phosphate (Na2HPO4), potassi-
um dihydrogen phosphate (KH2PO4), and trifluoroacetic
acid (TFA) were purchased from Fluka (Saint Quentin
Fallavier, France). VCV.HCl (99.5% purity) was purchased
from Sequoia Research Products (Oxford, United Kingdom).
All the solutions were prepared using de-ionized water
(resistivity >18 MW cm).
Porcine ear skin, which is a well-accepted model for
human skin (33,34), was used in these studies. Porcine ears
were obtained from a local abattoir (Socie´te´ d’Exploitation
d’Abbatage, Annecy, France) a few hours after the sacrifice
of the animals. The excised skin was then dermatomed
(õ750 mm) on the same day and stored at j20-C for a
maximum period of up to 2 months.
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Fig. 1. Structure of (a) VCV (MW 324.4 Da) (R-H represents ACV; MW 225.2 Da)
and (b) acetaminophen (MW 151.2 Da). (c) The molecular charge of ACV and VCV
(hollow and filled circles, respectively) as a function of pH. Under typical iontophoretic
conditions (i.e., pH 4Y7), the prodrug, VCV, carries a net positive charge unlike its active
metabolite, ACV.
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Iontophoresis Experiments
Iontophoresis was performed using vertical three-com-
partment cells. The skin was placed between two half-cells:
the upper half, in contact with the SC, comprised two
electrode/donor compartments, while the lower receiver
compartment was in contact with the dermis. A flow-through
system circulated phosphate-buffered normal saline (PBS:
16.8 mM Na2HPO4, 1.4 mM KH2PO4 and 136.9 mM NaCl;
pH 7.4) through the receiver chamber (volume õ4.7 ml) at a
rate of 3 ml hj1. Ag/AgCl electrodes were used throughout
the study. The skin was allowed to equilibrate for 1 h prior to
the iontophoresis experiment. In order to reduce competition
from Na+ ions present in the donor, and thus to increase the
permeation of VCV, most experiments were performed using
a salt bridge assembly. This strategy consists of physically
separating the anodal chamber (Ag electrode immersed in
PBS pH 7.4) from the donor compartment (drug solution in
contact with the SC) and employing a salt bridge (prepared
by filling a 12 cm tubing with a warm aqueous solution of 3%
agarose and 0.1 M NaCl which is then allowed to cool) to
electrically connect the two chambers. The donor contained
either 2 or 10 mM VCV.HCl in water, or 2 mM ACV in
2 mM NaCl. For control experiments without the salt bridge,
the anodal compartment contained 1 ml of 10 mM VCV.HCl
in PBS pH 7.4. The cathodal and receiver compartment
contained PBS pH 7.4 in all the experiments. A constant
current of 0.34 mA was applied for 7 h (equivalent to a
current density of 0.5 mA cmj2). For passive controls, the
donor contained 1 ml of 10 mM VCV.HCl in water or 2 mM
ACV in 2 mM NaCl.
Acetaminophen (ACE, CACE = 15 mM) was included in
the donor solution as a marker for electroosmotic flow
(Fig. 1b). Being a small, polar and neutral molecule, it is
transported mainly by convective solvent flow during ionto-
phoresis. Therefore, its flux (JACE) can be used to determine
the contribution of electroosmosis to the total iontophoretic
flux of VCV,
JEO;VCV ¼ vA!C  CVCV ð1Þ
where JEO,VCV represents the contribution of electroosmosis
(EO) to VCV delivery; vA!C is the convective solvent flow
from the anode to cathode (calculated from JACE/CACE) and
CVCV is the concentration of VCV in the donor compart-
ment. Two assumptions are implicit in this analysis: (a) that
drug and acetaminophen are transported in a similar fashion
by convective solvent flow, and (b) that electroosmotic
transport of the marker molecule is proportional to its
concentration in the solvent.
The experiments were performed in sextuplicate, except
for passive delivery (n = 3), using the skin of as many
different animals as possible. Samples were collected hourly
and analyzed by high pressure liquid chromatography
(HPLC). The HPLC system consisted of a 600 E Controller
pump, an Autosampler Injector 717-plus, an In Line Degas-
ser, and a UV 2487 dual l Detector (Waters, Saint-Quentin
Yvelines, France). The separation was performed on a
Nucleosil\ 100-5 C18 Nautilus column (L:125 mm; ID: 4.6
mm; Macherey-Nagel, Hoerdt, France) with a 99:1 mixture of
0.1% trifluoroacetic acid (TFA) in water (pH 2.5): MeCN.
The flow rate was 1 ml minj1, the temperature was adjusted
to 30-C, and 50 ml of sample were injected. ACV, ACE and
VCV were separated after 5.6, 14.4 and 19.1 min,
respectively, and detected at 252 nm (ACV and VCV) and
243 nm (ACE), enabling simultaneous analysis of the
prodrug, drug and electroosmotic marker. The limits of
detection/quantification for ACV, VCV and ACE were
approximately 0.1/0.3, 0.25/0.8, and 0.2/0.6 mM, respectively.
VCV Stability
The aqueous stability of VCV in the donor formulations
was investigated by periodic sampling of solutions (2 and
10 mM in water + 15 mM acetaminophen) over a period of
44 h. In addition, the impact of an electrical current (0.34 mA)
on this stability was examined over the same period. The
chemical hydrolysis of VCV was also investigated in the
presence of PBS pH 7.4. The cutaneous conversion of VCV
to ACV via hydrolytic cleavage of the ester bond was verified
as follows. Cells were assembled as for an iontophoresis
experiment. A 100 mM solution of VCV in PBS pH 7.4 was
placed in all the cell compartments and left in contact with
the skin (SC and dermis) for 4 h. The compartments were
assayed for ACV and VCV immediately afterwards. Finally,
the same experiment was performed with a 100 mM solution
of ACV, to examine the stability of ACV when in contact
with the skin.
RESULTS AND DISCUSSION
VCV Stability
Unbuffered aqueous solutions of VCV (2 mM: pH 5.65
and 10 mM: pH 5.24) were very stable in the presence of
acetaminophen for the duration of the investigation (44 h).
Less than 1% of the VCV was converted into ACV over this
time-period in the absence of a current; the extent of
degradation was slightly increased in the presence of a
current but nevertheless represented only õ1% over the
duration of an iontophoresis experiment (7 h). As mentioned
above, VCV as supplied contained small amounts of ACV
(0.5%). However, regeneration of ACV from the prodrug
was significantly enhanced at physiological pH (in PBS pH
7.4) as previously reported (35) with õ12% of the prodrug
being converted over 7 h.
After 4 h of contact with the dermis, VCV was
completely hydrolyzed to ACV and only the latter was
detected in the receiver (dermal) compartment, at physio-
logical pH. In contrast, after an equivalent contact period
with the SC, enzymatic conversion of VCV was not observed.
When ACV was similarly tested, the drug placed in both
donor and receptor chambers was stable for the duration of
the experiment. Although the data indicate that esterase
activity is present in the skin tissue despite prior storage of
the skin samples at j20-C (as previously reported (36)), the
extent of residual activity was not ascertained in the current
investigation; it is of course possible that prodrug conversion
in vivo proceeds with even greater efficiency.
Taken together, these preliminary observations sup-
ported the practical feasibility of VCV iontophoresis for
enhanced delivery of ACV to the deeper skin layers. Since
VCV was unaffected by the SC, it was reasonable to antic-
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ipate that this cationic prodrug could be iontophoretically
delivered to the viable epidermis at enhanced rates and levels
compared to the uncharged ACV, before being converted to
the active moietyVeither in the viable epidermis or in the
dermis.
Passive Delivery
Neither ACV nor VCV could be measured in the
receiver after passive delivery from formulations containing
10 mM VCV.HCl in water or 2 mM ACV in 2 mM NaCl. In
view of the analytical limit of detection of ACV in the cur-
rent study (õ0.13 mM), the passive fluxes of ACV and VCV
can be considered to be inferior to 1 nmol cmj2 hj1. This is
not surprising considering their polar nature (calculated log
DpH7 values are j1.76 and j1.71, for ACV and VCV,
respectively (37), and the aqueous formulation used, from
which partitioning of these molecules into the lipidic stratum
corneum is not favoured. These passive estimates are not
dissimilar to the in vitro flux values of ACV observed across
human (0.24 nmol cmj2 hj1) and guinea pig (0.21 nmol cmj2
hj1) skin from 5% w/w (õ220 mM; 100-fold higher
concentration compared to present work) ACV ointment
(8). The topical application of a 220 mM ACV formulation to
rabbits in vivo resulted in dermal concentrations (monitored
by microdialysis) that were also below the limit of detection
(18). Of course, this is not necessarily indicative of poor skin
penetration. Indeed, topical formulations are designed to
target the medicament to the site of action within the skin
tissue and as such employ quantities which are far inferior to
those administered systemically for equivalent effect. Drug
reaching the highly vascularized dermal papillary layer
subsequent to epidermal permeation is rapidly taken up
into the general circulation but is difficult to detect by virtue
of the rapid and extensive Fdilution_ of these modest drug
amounts. This has been demonstrated, to a certain extent, for
commercially available topical ACV formulations (Zovirax\),
which contain excipients (such as propylene glycol) to facilitate
ACV penetration into the SC. In various in vitro and in vivo
model systems, the topical administration of 5% w/
w Zovirax\ ointment and cream formulations resulted in
total epidermal levels that far exceeded therapeutic levels but
systemic levels that were analytically non-detectable.
However, despite therapeutically acceptable epidermal
levels of ACV, model predictions suggest that inadequate
antiviral levels in the basal epidermisVthe site of HSV type-1
infection, compromise topical therapy (11). In the
experiments described here, ACV delivery was assessed by
measurement of receptor levels subsequent to transport of
the prodrug or drug across dermatomed porcine ear skin
(õ750 mm). Hence, although ACV levels at the site of action
were not monitored, receptor concentrations adjacent to the
dermis were considered to provide a Bballpark^ estimate of
those in the basal epidermis in view of previously reported
skin distribution profiles for ACV (11,17,38).
Iontophoretic Permeation
Though neither ACV nor VCV could be delivered
passively across the skin, application of an iontophoretic
current (0.5 mA cm2) enhanced the percutaneous transport
of both these molecules, albeit to different extents. In certain
isolated cases, minute amounts of VCV (<2% of ACV levels
in receptor) could also be detected and measured in the
receiver subsequent to VCV iontophoresis, implying
incomplete VCV metabolism. In such cases, both ACV and
VCV concentrations were summed to determine the total
iontophoretic flux of VCV.
As shown in Fig. 2, receptor levels of ACV were
significantly greater subsequent to the iontophoresis of
VCV compared to that of ACV, when delivered from
equimolar formulations (2 mM, 0.5 mA cmj2). Although
ACV was not detected in the receiver compartment after 1 h,
and only modest amounts were present after 2 h of ACV
iontophoresis (0.1 mg cmj2), the cumulative permeation of
ACV at the corresponding time-points was much greater
upon VCV iontophoresis (20 T 10 and 104 T 47 mg cmj2,
respectively). After 3 h of current application nearly 200-fold
greater levels of ACV (194 T 82 vs. 1.0 T 0.7 mg cmj2) were
monitored in the receptor using a 2 mM solution of the
prodrug instead of the parent molecule. The experimental
data, therefore, clearly demonstrate that VCV is better suited
to iontophoretic delivery relative to its active metabolite,
ACV. Moreover, the dissimilar transport kinetics, together
with the preliminary hydrolysis assays, indicate that the
prodrug is promptly converted to its active metabolite, after
passage through the stratum corneum in the vicinity of the
epidermal and/or dermal tissues. Since topical delivery of a
therapeutic agent results in the establishment of a con-
centration gradient from the SC towards the subcutaneous
tissues, we can expect (all else being equal) ACV concen-
trations in the receptor to reflect those in the basal
epidermis.
Although, at first glance, cumulative ACV transport
appeared to be enhanced upon increasing donor VCV
concentration from 2 to 10 mM, strict comparison was
confounded by donor depletion at the lower applied dose.
Indeed, at the lower donor concentration, the amount that
had reached the receptor after only 4 h was equivalent to
50% of the applied dose. Importantly, the average flux over
the first 3 h of current application (Jt=0j3h) was not sig-
nificantly different ( p < 0.05) for the two formulations (2
mM: 87 T 41 mg cmj2 hj1; 10 mM: 108 T 65 mg cmj2 hj1).
Given the virtual absence of a lag-phase and rapid attainment
Fig. 2. Cumulative amount of ACV in the receptor compartment
after iontophoresis of ACV (2 mM; in the presence of 2 mM NaCl;
filled squares) and VCV (2 and 10 mM, in the absence of NaCl;
hollow and filled circles, respectively) at 0.5 mA cmj2 across porcine
skin in vitro. (Mean T SD; n = 6).
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of steady-state kinetics within the same time-frame for the
10 mM formulation (Jt=0j3h = 108 T 65 vs. Jt=0j7h = 115 T 52
mg cmj2 hj1) the observed Jt=0j3 for the lower concentration
was also assumed to approximate the steady-state value. That
is to say, in the event of donor replenishment, the
iontophoretic transport kinetics for VCV at 2 mM were not
expected to differ from that observed for the 10 mM
formulation. This non-dependence of flux on donor
concentration has been previously reported for the
hydrochloride salts of hydromorphone, methylphenidate,
lidocaine, quinine and propranolol when delivered from
formulations deficient in competitive charge carriers, e.g.,
those originating from buffer systems (39Y41).
The efficiency of iontophoretic drug transport is influ-
enced by formulation conditions including (a) donor electro-
lyte levelsVmobile inorganic ions compete very effectively
with higher molecular weight drug molecules to carry the
current (42) and (b) pH and its effect on the degree of
ionization of the drug molecule. The impact of these factors
was evaluated in a series of control experiments conducted
without a salt bridge assembly where the anodal/donor
compartment contained 10 mM VCV.HCl in PBS pH 7.4
(170.5 mM Na+; 1.4 mM K+). The resulting fluxes are
depicted in Fig. 3, which clearly shows the reduction in
transport rates as competing ion levels and pH are increased
(VCV steady-state flux decreased from õ120 to õ30 mg cmj2
hj1 in the presence of background electrolyte). In the PBS
formulation, the mobile Na+ ions were present in õ17-fold
excess to the VCV; furthermore at pH 7.4, the degree of
ionization of the latter is only 53% (cf. >99% at pH 5.2).
The iontophoretic flux (JTOT) of a charged species is
considered to be the sum of two separate transport
processesVelectromigration (JEM) and electroosmosis
(JEO), assuming negligible passive skin permeability (43):
JTOT;VCV ¼ JEM;VCV þ JEO;VCV ð2Þ
Since the EO contribution, JEO,VCV, was obtained as
described in the Materials and Methods (using Eq. 1), the
EM contribution, JEM,VCV, could be calculated by subtracting
JEO,VCV from the total flux, JTOT,VCV (using Eq. 2). Calcula-
tion of the respective EM and EO contributions to VCV
transport under the different formulation conditions showed
that VCV electromigration, JEM,VCV (after 7 h current
application) decreased from 118.9 to 24.6 mg cmj2 hj1, on
passing from 10 mM VCV.HCl in unbuffered aqueous
solution to 10 mM VCV.HCl in PBS at pH 7.4. This
significant decrease could not be compensated by any
increase in electroosmosis elicited by increasing formulation
pH (JEO,VCV was 4.5 and 9.2 mg cm
j2 hj1, in unbuffered
aqueous solution (pH 5.24) and in PBS at pH 7.4,
respectively).
The iontophoretic delivery of ACV across human and
nude mouse skin has been previously investigated at pH 3.0
(20% ionized) and at pH 7.4 (2% ionized) (16,17). The donor
concentration-normalized ACV fluxes across porcine skin at
pH 6.3, in the present study (2.4 10j3 cm hj1) over 7 h of
ACV iontophoresis compare favourably with those across
human skin at physiological pH (2.7 10j3 cm hj1) (17). In
the studies with human skin, the distribution of ACV across
various skin layers was also examined; although ionto-
phoresis generally enhanced total skin concentrations of
ACV, only formulations at pH 3.0 produced a significant
impact on the epidermal levels of the antiviral agent. It
should be noted that, in the current study, the donor con-
centration-normalized flux measured for the 2 mM VCV
formulation over the initial 3 h of current application is
approximately 50 times greater (0.13 cm hj1) than the
corresponding value for ACV.
Mechanism of Iontophoretic ACV and VCV Transport
The mechanism governing the iontophoretic transfer of
each molecule across the skin was evaluated by virtue of the
simultaneous measurement of acetaminophen (44), a neutral
molecule, transported principally by electroosmosis (EO).
While ACV was transported across the skin entirely by EO,
delivery of the prodrug was due almost entirely to electro-
migration (EM). The two distinct transport mechanisms for
each molecule reflect their ionization state in the respective
donor formulations. The unbuffered ACV and VCV for-
mulations had pH values of õ6.3 and 5.7, respectively; under
these conditions, ACV is effectively uncharged (>99.9%
neutral) while VCV is fully protonated in the donor phase.
Consequently, the transport of uncharged ACV is mediated
by convective solvent movement, whilst that of the proton-
ated VCV is facilitated by electromigration from the anodal
electrode. When donor electrolyte levels were increased, the
EM contribution to the total VCV flux was reduced from 96
to 73%, due to competition from Na+ ions in the formulation
to transport charge across the membrane.
As Fig. 4 shows, in the absence of competing ions
(jNa+), acetaminophen transport (reflecting the EO
contribution) was significantly influenced by donor levels of
VCV ( p < 0.05). Basal levels of acetaminophen transport
were unaffected by the presence of either 2 mM VCV or
ACV or 10 mM VCV in the presence of NaCl ( p < 0.05).
However, when NaCl was removed from the VCV
formulation, and drug transport accounted for a greater
proportion of current passage, acetaminophen transport
decreased significantly ( p < 0.05). This suggests that the
increase in VCV transport, resulting in greater amounts of
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VCV entering into the membrane, facilitated interactions
with the skin that reduced convective solvent flow, as has
been demonstrated previously for other cationic species
(41,44). This phenomenon tends to have a negative impact
on total iontophoretic transport (e.g., in the presence of
background electrolyte, flux may not be linearly proportional
to applied dose), and is considered to reduce the benefits of
Bcontrolled-delivery^ generally offered by iontophoresis.
However, for molecules such as VCV, which are overwhelm-
ingly transported by EM (õ96%), the impact of modifying EO
on overall transport is virtually imperceptible.
The studies described here were conducted with porcine
skin, therefore, we have to consider how these would
correlate with their human equivalent. Although species
dependent differences in hydrolysis rates have been observed
for certain molecules, the hydrolysis of several structurally
different ester derivatives suggests that human skin possesses
considerable esterase activity (45Y50): (a) Stinchcomb et al.,
demonstrated that several 3-alkyl ester prodrugs of bupre-
norphine were competely hydrolysed during passage through
human skin (45); (b) Bundgaard et al., found that a series of
acyloxymethyl ester prodrugs of nalidixic acid were com-
pletely hydrolysed during transit through human skin (46);
(c) Nicolau and Yacobi showed that the prostaglandin
analogue, viprostol, was 66% hydrolyzed to the free acid in
human skin (47) (d) Seki et al., found that the hexanoate
ester of zidovidudine was completely hydrolyzed upon
passage through human skin (however, the acetate derivative
was more resistant to cleavage) (48); (e) studies have also
shown that both animal and human skins are capable of
hydrolyzing corticosteroid 21-monoesters (49); (f) similarly,
glycerol trinitrate was found to be extensively hydrolyzed to
the 1,2 and 1,3 dinitrate derivatives following application to
human skin in vitro (50). Ta¨uber and Rost have also
demonstrated that in human skin, esterase activity in the
epidermis (calculated per mg of tissue wet weight) was õ10-
fold higher than that in the dermis (49), suggesting that there
would be considerable VCV metabolism and its biotransfor-
mation into the active metabolite, ACV, during its transit
through the epidermis and before reaching the basal
layersVthe site of infection.
Therapeutic Advantages of VCV Iontophoresis
Previous studies have shown that the iontophoretic
administration of ACV across human skin results in epider-
mal concentrations (õ80 mg cmj3), which are well above
those required for viral inhibition (17). Nevertheless, since
iontophoretic efficiency is dependent on the electrical
mobility of the drug, the electrotransport of charged species
is clearly favoured; for ACV, this is only possible in relatively
acidic formulations (pKa = 2.27). In contrast, the dissociation
profile of VCV is much more conducive to iontophoretic
delivery, allowing anodal delivery from formulations at
more physiologically acceptable pH (Fig. 1c). Indeed, our
results show that VCV iontophoresis for 3 h is almost 200-
times more efficient compared to iontophoretic ACV
delivery under equivalent conditions. In view of the
comparable ACV transport across porcine skin in the
present investigation and that previously observed across
human skin (17), which produced therapeutic levels within
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Fig. 5. Comparison of cumulative ACV permeation at steady state
following ACV iontophoresis across hairless mouse (after 4 h, (16)),
human (after 7 h (17)) and rabbit (after 7 h (19)) skin and VCV
iontophoresis across porcine skin (after 3 and 6 h, this study).
Columns 1Y4 shows the cumulative ACV amounts after anodal
iontophoresis at pH 7.4 (7.73 mM) at current densities of 0.18, 0.25,
0.36 and 0.5 mA cmj2, respectively; column 5 shows the results after
cathodal iontophoresis at pH 7.4 (7.73 mM) at 0.5 mA cmj2 across
hairless mouse skin in vitro. Columns 6 and 7 show cumulative ACV
amounts after anodal iontophoresis at pH 3.0 (6.88 mM) at current
densities of 0.25 and 0.5 mA cmj2, respectively; column 8 presents the
results after cathodal iontophoresis at pH 3.0 (6.88 mM) at 0.5 mA
cmj2. Columns 9 and 10 represent the cumulative ACV permeation
across human skin after anodal iontophoresis at pH 3.0 (6.88 mM)
and pH 7.4 (7.73 mM), respectively, at a current density of 0.5 mA
cmj2. Columns 11 and 12 display anodal and cathodal ACV delivery,
respectively, across rabbit skin (pH 3.0, 6.2 mM) at 0.125 mA cmj2.
Columns 13Y16 show cumulative ACV permeation across rabbit skin
from a formulation at pH 5.8 (4.2 mM) after anodal iontophoresis at
0.06, 0.125, 0.25 and 0.5 mA cmj2, respectively. Columns 17 and 18
show the cumulative ACV permeation after 3 and 6 h, respectively,
of VCV iontophoresis (pH 5.24, 10 mM, this study) at a current
density of 0.5 mA cmj2. Column 19 shows the cumulative ACV
permeation after 3 h of VCV iontophoresis (pH 5.65, 2 mM, this
study) at a current density of 0.5 mA cmj2. The data confirm that
cumulative ACV delivery is significantly more efficient following
VCV iontophoresis.
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the skin, the therapeutic superiority of VCV iontophoresis is
evident. Figure 5 compares the cumulative amount of ACV
permeated across hairless mouse (16), human (17) and rabbit
(19) skin after ACV iontophoresis under a series of
experimental conditions to that observed in the present study
upon VCV iontophoresis across porcine skin. It demonstrates
that ACV permeation was significantly greater following
VCV iontophoresis using milder formulation conditions. A
further advantage offered by the electrically mediated
delivery of the prodrug is the rapidity with which steady-
state kinetics are achieved, permitting short application
times, which would obviously be a significant advantage in
a therapeutic system (Fig. 3).
Given the iontophoretic transport efficiency of VCV
(transport number õ0.03, calculated from JEM,VCV after
iontophoresis for 7 h), it is clear that clinically efficacious
dosing is likely to be achieved with significantly reduced
doses and/or more innocuous currents. For example, in view
of the results here, a 10-fold reduction in applied current
density (to 0.05 mA.cmj2, a value 10-fold lower than the so-
called Blimit of tolerability^ (51)) is still likely to achieve skin
concentrations well above the therapeutic levels previously
reported.
CONCLUSIONS
This study demonstrates, unequivocally, the superiority
of VCV iontophoresis over that of the parent molecule,
ACV, to deliver the latter to the skin tissues. In doing so, it
illustrates the pivotal role of drug physical chemistry in
cutaneous iontophoretic transport and serves to emphasize
the impact of drug design on therapeutic efficiency. Though
drugs are rarely custom-designed for the chosen route of
administration, it is clear that relatively minor chemical
modifications can dramatically alter their transport behav-
iour across a given biological membrane.
With respect to topical applications, the presence of
esterase and peptidase activity (principally) in the viable skin
layers and, therefore, after passage across the rate-limiting
stratum corneum, (27,36,45Y50,52,53) opens the door for
many iontophoretic applications using prodrugs comprising
peptide or ester bonds which are susceptible to enzymatic
hydrolysis.
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